Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Demmer Irina; Huschens Susanne; Potthoff Dietrich; Tomeczkowski Joerg; Englisch Christian; Thilakarathne Pushpike; Diels Joris; Kumar Shaji K.; Durie Brian G. M.; Eisele Lewin

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

【24h】

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

机译：间接比较使用单独的患者水平数据进行比较达拉姆宫单药治疗的疗效和安全性与欧盟批准了多发性骨髓瘤患者的比较器疗法

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Demmer Irina; Huschens Susanne; Potthoff Dietrich; Tomeczkowski Joerg; Englisch Christian; Thilakarathne Pushpike; Diels Joris; Kumar Shaji K.; Durie Brian G. M.; Eisele Lewin;
展开▼
作者单位

Janssen Cilag GmbH Hlth Econ Market Access &

Reimbursement Neuss Germany;

Janssen Cilag GmbH Hlth Econ Market Access &

Reimbursement Neuss Germany;

Janssen Cilag GmbH Hlth Econ Market Access &

Reimbursement Neuss Germany;

Janssen Cilag GmbH Hlth Econ Market Access &

Reimbursement Neuss Germany;

Janssen Cilag GmbH Med Affairs Neuss Germany;

Janssen Hlth Econ &

Market Access EMEA Stat &

Mod Beerse Belgium;

Janssen Hlth Econ &

Market Access EMEA Stat &

Mod Beerse Belgium;

Mayo Clin Div Hematol Rochester MN USA;

Cedars Sinai Outpatient Canc Ctr Samuel Oschin Comprehens Canc Inst Los Angeles CA USA;

Janssen Cilag GmbH Hlth Econ Market Access &

Reimbursement Neuss Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma [J] . Demmer Irina, Huschens Susanne, Potthoff Dietrich, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：间接比较使用单独的患者水平数据进行比较达拉姆宫单药治疗的疗效和安全性与欧盟批准了多发性骨髓瘤患者的比较器疗法
2. Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) [J] . Voorhees Peter M., Rodriguez Cesar, Reeves Brandi, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：来自Griffin的安全运行队列的疗效和更新安全分析，达拉姆宫（Dara），Bortezomib（V），Lenalalomide（r）和地塞米松（D; Dara-VRD）与地区的第2期随机研究患者（PTS）中的VRD与新诊断（ND）多发性骨髓瘤（MM）有资格获得高剂量治疗（HDT）和自体干细胞移植（ASCT）
3. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients [J] . Jelinek Tomas, Maisnar Vladimir, Pour Ludek, Current medical research and opinion . 2018,第5期

机译：在捷克共和国的捷克共和国对捷克共和国的真实世界历史控制数据的调整后比较，高难治性多发性骨髓瘤患者
4. Carbapenems As a Second Line Empirical Monotherapy in Patients with Hematological Malignances, Neutropenia and Fever [C] . A. Candoni, C. Fill, C. Skert, European Haematology Association . 2002

机译：Carbapenems作为血液恶性恶性肿瘤，中性粒细胞病和发烧患者的二线实证单一疗法
5. A comparative study of quality of life in patients with low-and intermediate-risk prostate cancer treated at a single institution: Stereotactic radiotherapy vs. high dose-rate brachytherapy monotherapy vs. high dose-rate brachytherapy boost [D] . Helou, Joelle. 2017

机译：单一机构治疗的中低危前列腺癌患者生活质量的比较研究：立体定向放疗与高剂量率近距离放射疗法单药疗法与高剂量率近距离放射疗法增强
6. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison [O] . Saad Z. Usmani, Joris Diels, Tetsuro Ito, -1

机译：在高度预处理和高度难治的多发性骨髓瘤患者中Daratumumab单药治疗与历史对照数据的比较：调整后的治疗比较
7. Indirect Comparison Of Daratumumab Monotherapy Versus Real-World Historical Control Data In Patients With Multiple Myeloma Who Are Heavily Pre-Treated And Highly Refractory [O] . J Diels, A Lam, T Ito, 2016

机译：无小石Monotherapy与真实世界历史控制数据的间接比较，患有多种骨髓瘤的患者严重预处理和高难治性

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

著录项

相似文献

相关主题

期刊订阅